Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion
BACKGROUND AND OBJECTIVE: To determine the effectiveness and direct medical costs of treat-and-extend (TAE) intravitreal bevacizumab (IVB) for the treatment of branch retinal vein occlusion (BRVO) - associated macular edema (ME). PATIENTS AND METHODS: Retrospective chart review of 52 consecutive pat...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Slack Incorporated
2014
|
| _version_ | 1826270594830696448 |
|---|---|
| author | Rush, R Simunovic, M Aragon, A Ysasaga, J |
| author_facet | Rush, R Simunovic, M Aragon, A Ysasaga, J |
| author_sort | Rush, R |
| collection | OXFORD |
| description | BACKGROUND AND OBJECTIVE: To determine the effectiveness and direct medical costs of treat-and-extend (TAE) intravitreal bevacizumab (IVB) for the treatment of branch retinal vein occlusion (BRVO) - associated macular edema (ME). PATIENTS AND METHODS: Retrospective chart review of 52 consecutive patients diagnosed with BRVO-associated ME treated with IVB using a TAE protocol. RESULTS: Mean change in logMAR vision was -0.30 (P < .001), and mean change in central macular thickness was -244.0 μm (P < .001). The mean number of injections was 8.2 (95% CI; 7.8 to 8.6). The yearly average direct cost of the TAE regimen was calculated to be $2,580.26 per patient. CONCLUSION: Treatment of BRVO-associated ME with IVB using a TAE regimen resulted in similar visual outcomes and number of intravitreal injections as did as-needed treatment with 0.5 mg ranibizumab conducted in phase 3 trials but with fewer visits and lower annual medical costs. |
| first_indexed | 2024-03-06T21:43:18Z |
| format | Journal article |
| id | oxford-uuid:48ae951c-cb66-4328-ae78-d6c42ee57ba2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:43:18Z |
| publishDate | 2014 |
| publisher | Slack Incorporated |
| record_format | dspace |
| spelling | oxford-uuid:48ae951c-cb66-4328-ae78-d6c42ee57ba22022-03-26T15:27:13ZTreat-and-extend intravitreal bevacizumab for branch retinal vein occlusionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:48ae951c-cb66-4328-ae78-d6c42ee57ba2EnglishSymplectic Elements at OxfordSlack Incorporated2014Rush, RSimunovic, MAragon, AYsasaga, JBACKGROUND AND OBJECTIVE: To determine the effectiveness and direct medical costs of treat-and-extend (TAE) intravitreal bevacizumab (IVB) for the treatment of branch retinal vein occlusion (BRVO) - associated macular edema (ME). PATIENTS AND METHODS: Retrospective chart review of 52 consecutive patients diagnosed with BRVO-associated ME treated with IVB using a TAE protocol. RESULTS: Mean change in logMAR vision was -0.30 (P < .001), and mean change in central macular thickness was -244.0 μm (P < .001). The mean number of injections was 8.2 (95% CI; 7.8 to 8.6). The yearly average direct cost of the TAE regimen was calculated to be $2,580.26 per patient. CONCLUSION: Treatment of BRVO-associated ME with IVB using a TAE regimen resulted in similar visual outcomes and number of intravitreal injections as did as-needed treatment with 0.5 mg ranibizumab conducted in phase 3 trials but with fewer visits and lower annual medical costs. |
| spellingShingle | Rush, R Simunovic, M Aragon, A Ysasaga, J Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion |
| title | Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion |
| title_full | Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion |
| title_fullStr | Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion |
| title_full_unstemmed | Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion |
| title_short | Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion |
| title_sort | treat and extend intravitreal bevacizumab for branch retinal vein occlusion |
| work_keys_str_mv | AT rushr treatandextendintravitrealbevacizumabforbranchretinalveinocclusion AT simunovicm treatandextendintravitrealbevacizumabforbranchretinalveinocclusion AT aragona treatandextendintravitrealbevacizumabforbranchretinalveinocclusion AT ysasagaj treatandextendintravitrealbevacizumabforbranchretinalveinocclusion |